Immune Checkpoints Contribute Corneal Immune Privilege: Implications for Dry Eye Associated with Checkpoint Inhibitors.
Animals
Anterior Chamber
/ immunology
B7-H1 Antigen
/ metabolism
Cornea
/ immunology
Corneal Transplantation
Dry Eye Syndromes
/ immunology
Fas Ligand Protein
/ metabolism
Graft Rejection
/ immunology
Humans
Immune Privilege
/ immunology
Immune System
Immune Tolerance
Immunologic Factors
Immunosuppressive Agents
/ therapeutic use
Inflammation
Ligands
T-Lymphocytes
/ immunology
T-Lymphocytes, Regulatory
/ immunology
fas Receptor
/ metabolism
V-domain Ig suppressor of T cell activation
anterior chamber-associated immune deviation
corneal transplantation
dry eye
immune checkpoints
immune privilege
immune-related adverse events
programmed death ligand-1
programmed death-1
regulatory T cells
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
31 May 2020
31 May 2020
Historique:
received:
30
04
2020
revised:
30
05
2020
accepted:
30
05
2020
entrez:
4
6
2020
pubmed:
4
6
2020
medline:
2
4
2021
Statut:
epublish
Résumé
The eye is provided with immune protection against pathogens in a manner that greatly reduces the threat of inflammation-induced vision loss. Immune-mediated inflammation and allograft rejection are greatly reduced in the eye, a phenomenon called 'immune privilege'. Corneal tissue has inherent immune privilege properties with underlying three mechanisms: (1) anatomical, cellular, and molecular barriers in the cornea; (2) an immunosuppressive microenvironment; and (3) tolerance related to regulatory T cells and anterior chamber-associated immune deviation. This review describes the molecular mechanisms of the immunosuppressive microenvironment and regulatory T cells in the cornea that have been elucidated from animal models of ocular inflammation, especially those involving corneal transplantation, it also provides an update on immune checkpoint molecules in corneal and systemic immune regulation, and its relevance for dry eye associated with checkpoint inhibitor therapy.
Identifiants
pubmed: 32486493
pii: ijms21113962
doi: 10.3390/ijms21113962
pmc: PMC7312178
pii:
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
Fas Ligand Protein
0
Immunologic Factors
0
Immunosuppressive Agents
0
Ligands
0
fas Receptor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Society for the Promotion of Science
ID : 20K09813 and 20K18362
Références
J Clin Invest. 1995 Jan;95(1):82-8
pubmed: 7814649
Adv Immunol. 1977;25:1-54
pubmed: 345773
Immunity. 1999 Aug;11(2):141-51
pubmed: 10485649
Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6216-21
pubmed: 9177197
Invest Ophthalmol Vis Sci. 2000 Sep;41(10):3032-42
pubmed: 10967061
Eur J Immunol. 1992 Jan;22(1):165-73
pubmed: 1530916
Immunity. 1999 Oct;11(4):423-32
pubmed: 10549624
J Immunol. 1977 Mar;118(3):809-14
pubmed: 321682
Eye (Lond). 2009 Apr;23(4):756-66
pubmed: 18989350
Invest Ophthalmol Vis Sci. 2009 Jan;50(1):263-72
pubmed: 18775867
Nat Immunol. 2003 Nov;4(11):1102-10
pubmed: 14556006
J Immunol. 1978 Mar;120(3):689-93
pubmed: 632581
Br J Exp Pathol. 1948 Feb;29(1):58-69
pubmed: 18865105
J Immunol. 2006 Nov 1;177(9):5928-35
pubmed: 17056517
Cell Mol Immunol. 2018 May;15(5):438-446
pubmed: 29375120
J Exp Med. 2003 Jul 7;198(1):161-71
pubmed: 12835481
J Biol Chem. 1999 Jul 16;274(29):20049-52
pubmed: 10400609
J Immunol. 1994 Sep 1;153(5):1982-9
pubmed: 8051403
Science. 1995 Mar 10;267(5203):1449-56
pubmed: 7533326
Curr Opin Cell Biol. 1999 Apr;11(2):255-60
pubmed: 10209153
J Clin Oncol. 2015 Jun 10;33(17):1974-82
pubmed: 25605845
J Exp Med. 2012 Feb 13;209(2):201-9
pubmed: 22330682
Science. 2007 Nov 16;318(5853):1141-3
pubmed: 18006747
Curr Opin Oncol. 2016 Jul;28(4):288-94
pubmed: 27136135
Science. 1995 Nov 17;270(5239):1189-92
pubmed: 7502042
BMJ. 2018 Mar 14;360:k793
pubmed: 29540345
Immunology. 1990 Dec;71(4):566-72
pubmed: 2149124
Transplantation. 1997 Oct 27;64(8):1107-11
pubmed: 9355824
EMBO J. 1992 Nov;11(11):3887-95
pubmed: 1396582
Prog Retin Eye Res. 2019 Sep;72:100758
pubmed: 31014973
J Immunol. 2011 Aug 15;187(4):1537-41
pubmed: 21768399
Invest Ophthalmol Vis Sci. 1998 Jul;39(8):1372-8
pubmed: 9660485
J Intern Med. 2003 Jan;253(1):18-30
pubmed: 12588535
Nat Immunol. 2006 Apr;7(4):354-9
pubmed: 16550198
J Exp Med. 2011 Mar 14;208(3):577-92
pubmed: 21383057
Nat Rev Immunol. 2003 Nov;3(11):879-89
pubmed: 14668804
Nat Rev Immunol. 2008 Jun;8(6):467-77
pubmed: 18500231
Invest Ophthalmol Vis Sci. 2010 May;51(5):2548-57
pubmed: 20007827
Nat Rev Immunol. 2002 Feb;2(2):116-26
pubmed: 11910893
Cell. 2015 Apr 9;161(2):205-14
pubmed: 25860605
Nat Immunol. 2005 Dec;6(12):1245-52
pubmed: 16286920
Invest Ophthalmol Vis Sci. 2011 Apr 20;52(5):2598-605
pubmed: 21245393
J Exp Med. 2007 Jul 9;204(7):1691-702
pubmed: 17606630
Int Rev Immunol. 2002 Mar-Jun;21(2-3):123-52
pubmed: 12424840
Immunol Rev. 2009 May;229(1):259-70
pubmed: 19426227
Adv Immunol. 1990;48:191-226
pubmed: 2190450
Nature. 1999 Dec 16;402(6763):827-32
pubmed: 10617205
J Clin Invest. 2008 Feb;118(2):742-51
pubmed: 18172549
J Immunol. 1998 Jun 15;160(12):5693-6
pubmed: 9637476
Nature. 1999 Jan 21;397(6716):263-6
pubmed: 9930702
Invest Ophthalmol Vis Sci. 2000 Feb;41(2):443-52
pubmed: 10670474
J Leukoc Biol. 2002 Nov;72(5):946-52
pubmed: 12429716
JAAD Case Rep. 2016 Jul 14;2(3):264-8
pubmed: 27486590
J Immunother. 2018 Sep;41(7):336-339
pubmed: 29787423
PLoS One. 2013 May 07;8(5):e63620
pubmed: 23667648
J Clin Invest. 1997 Feb 1;99(3):396-402
pubmed: 9022072
Nat Med. 2002 Aug;8(8):793-800
pubmed: 12091876
Invest Ophthalmol Vis Sci. 1989 Feb;30(2):323-9
pubmed: 2492486
Rheumatology (Oxford). 2019 Dec 1;58(Suppl 7):vii40-vii48
pubmed: 31816084
Biochem Biophys Res Commun. 2000 Jan 7;267(1):257-61
pubmed: 10623607
Biochem Biophys Res Commun. 2000 Sep 16;276(1):335-45
pubmed: 11006126
Invest Ophthalmol Vis Sci. 2016 Dec 1;57(15):6815-6823
pubmed: 28002569
FASEB J. 1987 Sep;1(3):199-208
pubmed: 2957263
J Clin Invest. 2014 May;124(5):1966-75
pubmed: 24743150
Cell. 1997 Feb 7;88(3):355-65
pubmed: 9039262
Science. 1998 Aug 28;281(5381):1305-8
pubmed: 9721089
Dermatology. 2009;218(1):69-70
pubmed: 18832811
Nat Med. 1999 Dec;5(12):1365-9
pubmed: 10581077
Cornea. 2016 Mar;35(3):399-401
pubmed: 26771550
Cell Immunol. 1992 Oct 1;144(1):80-94
pubmed: 1394442
Nature. 2002 Jan 31;415(6871):536-41
pubmed: 11823861
Invest Ophthalmol Vis Sci. 2000 Dec;41(13):4195-202
pubmed: 11095615
Immunity. 2004 Mar;20(3):327-36
pubmed: 15030776
Invest Ophthalmol Vis Sci. 2019 Dec 2;60(15):4958-4965
pubmed: 31790558
J Immunother Cancer. 2016 Dec 20;4:86
pubmed: 28031817
Acta Ophthalmol. 2009 Aug;87(5):488-97
pubmed: 19664109
Chem Immunol Allergy. 2007;92:27-35
pubmed: 17264480
Retina. 2018 Jun;38(6):1063-1078
pubmed: 29689030
Nat Immunol. 2003 Nov;4(11):1093-101
pubmed: 14556005
Curr Biol. 1999 Feb 25;9(4):215-8
pubmed: 10074428
Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6556-65
pubmed: 20702832
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373